Mavrakanas TA, et al. – In this meta-analysis of five randomized trials representing 1,902 patients with CKD, researchers investigated whether shorter dual antiplatelet therapy (DAPT) vs longer DAPT is associated with lower mortality or major adverse cardiovascular event rates in patients with drug-eluting stents and CKD. Eligible trials were identified from Medline and compared various DAPT duration strategies in patients with drug-eluting stents. A composite of all-cause mortality, myocardial infarction, stroke, or stent thrombosis (definite or probable) comprised the primary outcome. The secondary outcome was major bleeding. According to findings, shorter DAPT was not inferior to longer DAPT in this patient population. However, due to imprecision in estimates, the authors cautioned that no definitive conclusion can be drawn with regard to stent thrombosis.